BRCAness as an Important Prognostic Marker in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy: A Multicenter Retrospective Study
by
Yoshimasa Kosaka 1
, Yutaka Yamamoto 2, Hirokazu Tanino 3,*, Hiroshi Nishimiya 1, Mutsuko Yamamoto-Ibusuki 4, Yuko Hirota 5, Hirotaka Iwase 2, Seigo Nakamura 6 and Sadako Akashi-Tanaka 6
Yoshimasa Kosaka 1, Yutaka Yamamoto 2, Hirokazu Tanino 3,*, Hiroshi Nishimiya 1, Mutsuko Yamamoto-Ibusuki 4, Yuko Hirota 5, Hirotaka Iwase 2, Seigo Nakamura 6 and Sadako Akashi-Tanaka 6
1
Department of Breast and Endocrine Surgery, Kitasato University School of Medicine, Sagamihara 252-0374, Japan
2
Department of Breast and Endocrine Surgery, Graduate School of Medical Sciences Kumamoto University, Kumamoto 860-8556, Japan
3
Division of Breast Surgery, Department of Surgery, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan
4
Department of Molecular-Targeting Therapy for Breast Cancer, Kumamoto University Hospital, Kumamoto 860-8556, Japan
5
Department of Diagnostic Pathology, Showa University Koutou Toyosu Hospital, Koutou 135-8577, Japan
6
Department of Breast Surgical Oncology, Showa University School of Medicine, Shinagawa 142-8666, Japan
*
Author to whom correspondence should be addressed.
Diagnostics 2020, 10(2), 119; https://doi.org/10.3390/diagnostics10020119
Received: 29 December 2019 / Revised: 30 January 2020 / Accepted: 19 February 2020 / Published: 21 February 2020
(This article belongs to the Collection Biomarkers in Medicine)
Triple-negative breast cancer (TNBC) has several subtypes. The identification of markers associated with recurrence and poor prognosis in patients with TNBC is urgently needed. BRCAness is a set of traits in which BRCA1 dysfunction, arising from gene mutation, methylation, or deletion, results in DNA repair deficiency. In the current study, we evaluated the clinical significance and prognosis of BRCAness in a multicenter retrospective study. Ninety-four patients with TNBC treated with neoadjuvant chemotherapy were enrolled from three university hospitals for this retrospective study. BRCAness was evaluated in 94 core needle biopsy (CNB) specimens prior to neoadjuvant chemotherapy and 49 surgical specimens without pathological complete response (pCR). The samples were assessed using multiplex ligation-dependent probe amplification, and the amplicons were scored. Of the 94 patients, 51 had BRCAness in CNB specimens. There were no significant differences in pCR rates or recurrence between the BRCAness and non-BRCAness groups. Among surgical specimens, the BRCAness group had a significantly shorter recurrence-free survival and overall survival compared with the non-BRCAness group. The BRCAness of surgical specimens was found to be an important marker to predict prognosis in patients with TNBC after neoadjuvant chemotherapy. A clinical trial to assess the clinical impact of carboplatin with BRCAness is planned.
View Full-Text
Keywords:
breast cancer; BRCAness; triple-negative breast cancer; neoadjuvant chemotherapy; prognosis
▼
Show Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
MDPI and ACS Style
Kosaka, Y.; Yamamoto, Y.; Tanino, H.; Nishimiya, H.; Yamamoto-Ibusuki, M.; Hirota, Y.; Iwase, H.; Nakamura, S.; Akashi-Tanaka, S. BRCAness as an Important Prognostic Marker in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy: A Multicenter Retrospective Study. Diagnostics 2020, 10, 119.
Show more citation formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
Search more from Scilit
